Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03561298 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03561298 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 18 participants.
The verdict
NCT03561298, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and pharmacokinetic interaction of effects of multiple doses of zanubrutinib with a "Cocktail" of five probe drugs for cytochrome P450 (CYP) 3A, CYP2C9, CYP2C19, P-glycoprotein and breast cancer resistance protein (BCRP) in healthy subjects
Interventions
- DRUG BGB-3111 and Drug Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2018-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03561298
The ClinicalTrials.gov registry entry for NCT03561298 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BGB-3111 and Drug Cocktail is the first listed.
NCT03561298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03561298 about?
NCT03561298 is a clinical study titled "A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects". This study is designed to evaluate the safety and pharmacokinetic interaction of effects of multiple doses of zanubrutinib with a "Cocktail" of five probe drugs for cytochrome P450 (CYP) 3A, CYP2C9, CYP2C19, P-glycoprotein and breast cancer resistance protein (BCRP) in healthy subjects
What is the current status of trial NCT03561298?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-06-07. Estimated completion is 2018-07-02.
What interventions are being tested in trial NCT03561298?
The interventions under investigation include: BGB-3111 and Drug Cocktail (DRUG).
Who is sponsoring clinical trial NCT03561298?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.